Eli Lilly's experimental weekly injection retatrutide cut breathing interruptions by as much as 34.3 events per hour in two phase 3 trials of 691 adults with moderate-to-severe obstructive sleep apnea — results published in the New England Journal of Medicine that raise real hopes for a condition that goes undiagnosed in most sufferers, and sharp questions about who will pay for the cure.
The two trials, TRIUMPH-1-OSA and TRIUMPH-2-OSA, were randomized, placebo-controlled studies led by an international team headed by Ronald Grunstein. Together they enrolled 691 adults with moderate-to-severe obstructive sleep apnea and a body mass index of 27 or higher. Moderate-to-severe means at least 15 breathing pauses per hour of sleep. TRIUMPH-1-OSA enrolled 243 participants without type 2 diabetes. TRIUMPH-2-OSA enrolled 448 participants with the disease. Participants received weekly subcutaneous retatrutide at 4, 9 or 12 milligrams, or a placebo, for 80 weeks. Retatrutide is a triple agonist, meaning it targets three hormone receptors: GIP, GLP-1 and glucagon. Among participants without diabetes, the apnea-hypopnea index, the standard count of breathing pauses and shallow breaths per hour, fell by an average of 34.3 events on the 9 mg dose and 31.7 on the 12 mg dose. Placebo fell by 9.9 events. The 4 mg dose cut the index by 22.9 events per hour in the trial without diabetes and by 19.2 in the trial with diabetes. In the diabetes trial, the 12 mg dose cut it by 25.4 events per hour. Hypoxic burden, which tracks how often, how long and how deeply oxygen levels drop during sleep, fell by roughly 63 percent to 75 percent at the two higher doses across both trials. Placebo groups saw drops of 26 percent to 30 percent.
Placebo patients also improved, but in the trial without diabetes the 9 mg dose cut breathing events by an average of 34.3 per hour, against 9.9 for placebo.
The sleep apnea trials sit inside a much larger program. The broader TRIUMPH-1 study enrolled 2,339 adults with obesity or overweight and no diabetes. Over 80 weeks, mean weight loss was 17.6 percent at 4 mg, 23.7 percent at 9 mg and 25.0 percent at 12 mg, against 3.9 percent for placebo. Findings from that study were presented in June 2026 at the American Diabetes Association's 86th Scientific Sessions. On July 23, 2026, after five positive phase 3 studies, Lilly executive Kenneth Custer, president of Lilly Cardiometabolic Health, said retatrutide could be “an important future tool in the management of cardiometabolic health.” The company said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Until then the drug remains investigational and unapproved. Lilly already sells Zepbound, known generically as tirzepatide, and Foundayo, known generically as orforglipron. The National Sleep Foundation says obstructive sleep apnea affects more than 50 million Americans, and about 80 percent of cases go undiagnosed.
The results are impressive, and patients who gasp awake every night deserve better options. Nobody should wave away a treatment that sharply cuts breathing events. But a few cautions belong in the conversation. These trials were sponsored by Lilly, the company that stands to profit, and sponsor-run studies deserve the same independent scrutiny as any other. A drug taken weekly for 80 weeks to achieve these numbers is also a long-term commitment, and the price and insurance coverage will matter as much as the data. If taxpayer-funded programs end up footing the bill for millions of prescriptions, voters are entitled to ask whether lifestyle changes, existing CPAP machines and other proven tools were weighed fairly. Medicine should be judged on evidence and cost, not on hype. A promising trial is the start of that accounting, not the end of it. Patients and payers should demand to see the full long-term safety record before anyone treats a headline number as a guarantee.
The apnea-hypopnea index counts how many times per hour a sleeper stops breathing or breathes too shallowly. A drop of 34 events per hour does not necessarily mean a patient is cured; someone starting at a high baseline can improve dramatically and still have measurable apnea. Placebo groups also improved, which is why the comparison against placebo, not the raw drop alone, is the number that matters. The trials enrolled people with a body mass index of 27 or higher, so the findings apply to people who are overweight or obese, not to every apnea patient. The drug's weight loss itself likely drives part of the benefit, since excess weight is a major contributor to airway obstruction.
Source:Weight-loss drug could help address nighttime sleep disruptions for millions
Anyone who has tried to sleep next to a loud snorer, or been the snorer, knows how much a bad night costs the next day. A treatment that gives millions of people back their sleep would be a genuine achievement of American medicine. But a good trial is not a approved drug, and an approved drug is not an affordable one. The FDA filing is planned for the first quarter of 2027, and the questions about price, coverage and long-term safety will follow it. Applaud the science, then check the bill. Good news for sleepers should not become a bad surprise for taxpayers.